Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bristol-Myers Squibb; Merck & Co., Inc.; and Pfizer Inc.

Community Practice Connections™: 4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application

Release Date: February 7, 2020
Expiration Date: February 7, 2021
Media: Internet - based

Activity Overview

The expansion of immunotherapies into treatment regimens for multiple types of cancer continues to revolutionize the way that clinicians treat their patients and manage treatment-related toxicities. Real-world data and continued collection of clinical trial data on the use of combination therapies, more effective means of mitigating immune-related adverse effects (irAEs), and novel design of clinical trials create educational gaps for busy clinicians who strive to provide care that is at the forefront of clinical knowledge. This field is extremely clinically relevant and encompasses an opportunity for personalized medicine that is ignited with constant drug development in oncology.

This Community Practice Connection™ program is designed to assist clinicians in keeping up-to-date on the frontline developments in immuno-oncology and support innovative best practice treatment for patients with cancer. This online program is associated with the 4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, an exciting and fast-paced congress that focuses exclusively on immunotherapies and their application to the management of cancer. This program will provide a comprehensive review of significant data sets that are relevant to the application of novel strategies for the management of several types of cancer. The program will focus on the practical application of recent clinical trial results that directly influence clinical management and biomarker testing.

Topics of particular interest will be combination therapies with checkpoint inhibitors, identification of novel driver mutations, and the application of concepts related to immunotherapy for multiple types of cancer.

Benefits of Participating

  • Utilize the knowledge from experts and clinical trial pioneers on topics related to immune checkpoint blockade, cell-mediated immunotherapy, and clinical trial design.
  • Apply additional education to difficult cases or current points of discussion in immunotherapy.
  • Incorporate immunotherapy data into daily clinical decision making.
  • Explore important concepts related immunotherapy that have broad, practice-changing implications.
  • Prepare for possible incidence of short-term and long-term irAEs as applied in clinical scenarios.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bristol-Myers Squibb; Merck & Co., Inc.; and Pfizer Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and pulmonologists involved in the treatment and management of patients with cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Determine current and emerging mechanisms that underlie the rationale to target the immune system to treat various forms of cancer.
  • Explain recent evidence that informs the application of immunotherapeutic strategies and how these data can be practically applied to the management of cancer in multiple lines of care.
  • Identify next steps in the field of cancer immunotherapies based on key needs, as well as ongoing and planned trials designed to answer important unanswered clinical questions.
  • Integrate current and emerging testing approaches to stratify risk and optimize the use of immunotherapeutic strategies.
  • Apply knowledge on treatment-related toxicities to proactively mitigate and manage irAEs in patients who receive immunotherapeutic approaches to manage their cancer.

Faculty, Staff, and Planners’ Disclosures


Naiyer A. Rizvi
Naiyer A. Rizvi, MD
Professor of Medicine
Director, Thoracic Oncology
Co-Director, Cancer Immunotherapy Program
Price Chair, Clinical Translational Research
New York-Presbyterian/Columbia University
Irving Medical Center
New York, NY

Disclosures: Consultant: AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck & Co., Inc., Novartis, Pfizer Inc., Regeneron Pharmaceuticals, Lilly, Janssen Pharmaceuticals, GlaxoSmithKline, EMD Serono; Shareholder: Gritstone Oncology, Bellicum Pharmaceuticals, Brooklyn ImmunoTherapeutics.

Mario Sznol
Mario Sznol, MD
Professor, Internal Medicine (Medical Oncology)
Leader, Melanoma Disease Related Translational Team
Co-Leader, Cancer Immunology Program
Yale School of Medicine
Yale Cancer Center
New Haven, CT

Disclosures: Consultant: Genentech-Roche, Bristol-Myers Squibb, AstraZeneca/Medimmune, Novartis, Seattle Genetics, Biodesix, Modulate Therapeutics, NewLink Genetics, Molecular Partners, Innate Pharma, Torque Pharma, AbbVie, Immunocore, Genmab, Almac, Hinge Clinica, Allakos, Anaeropharma Science, Array BioPharma, GI Innovation, Genocea Biosciences, Chugai-Roche; Shareholder: Stock options only: Amphivena Therapeutics, Adaptive Biotechnologies, Intensity Therapeutics, Actym Therapeutics, Torque Pharma; Other: Scientific Advisory Boards: Symphogen, Adaptimmune, Omniox, Lycera, Pieris Pharmaceuticals, Torque Pharma.

Yelena Y. Janjigian
Yelena Y. Janjigian, MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: no relevant financial relationships with commercial interests to disclose.

Jeffrey S. Weber
Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Health
New York, NY

Disclosures: Grant/Research Support: Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., Incyte Corporation, Genentech all to Moffitt; Consultant: Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., Incyte Corporation, Genentech, AstraZeneca, Medivation; Shareholder: Altor BioScience, Celldex Therapeutics, cCAM Biotherapeutics, CytomX Therapeutics, Biond Biologics; Other: Named on a patent held by Moffitt Cancer Center that relates to a predictive marker for ipilimumab.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By